Neonc Technologies Holdings, Inc. (NTHI): R&D Expense
$3.64M
Year ended 2025-12-31
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.64M | +19.5% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $3.05M | n/a | 2026-03-31, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $340.0K | +22.3% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
Compare NTHI, ALT, LYEL, IBO side by side · Screen every company in Pharmaceutical Preparations ↗